Welcome to our dedicated page for Boston Scien Cp news (Ticker: BSX), a resource for investors and traders seeking the latest updates and insights on Boston Scien Cp stock.
Boston Scientific Corporation develops and markets less invasive medical devices and therapies used by healthcare professionals and institutions globally. News about BSX centers on operating results, business highlights, capital-structure updates and product developments across cardiovascular, respiratory, digestive, oncological, neurological and urological care.
Recurring company updates include clinical evidence and regulatory milestones for platforms such as FARAPULSE pulsed field ablation, WATCHMAN left atrial appendage closure, EKOS endovascular therapy and the Asurys Fluid Management System. Coverage also reflects conference presentations, FDA clearances, trial results and management discussions of quarterly performance across the company’s medical-technology portfolio.
Boston Scientific Corporation (NYSE: BSX) has announced a definitive agreement to acquire Baylis Medical Company for an upfront payment of $1.75 billion. This acquisition aims to enhance its electrophysiology and structural heart product lines by including advanced transseptal platforms that improve safety and efficiency for left heart procedures. Baylis is projected to generate $200 million in net sales in 2022, marking five years of double-digit growth. The deal is expected to close in Q1 2022, and is anticipated to be accretive to adjusted earnings per share.
Boston Scientific (NYSE: BSX) announced positive findings for its EkoSonic™ Endovascular System at the Vascular InterVentional Advances (VIVA) meeting in Las Vegas. The KNOCOUT PE registry, which studied 489 patients across 83 centers, demonstrated the system's safety and efficacy in treating pulmonary embolism (PE) with a lower drug dose and shorter infusion duration. Notably, no intracerebral hemorrhagic events occurred, and the major bleeding rate was just 2.5%. The results also indicated a 23% reduction in heart strain post-procedure, underscoring the system's potential to enhance patient care.
Boston Scientific announced positive results for the Ranger™ Drug-Coated Balloon (DCB) during the VIVA meeting in Las Vegas on October 5, 2021. The two-year results from the RANGER II SFA trial showed a primary patency rate of 84.0% for Ranger DCB, significantly higher than 71.4% for standard PTA (p=0.0129).
Also noted was an 87.4% freedom from target lesion revascularization for Ranger DCB versus 79.5% for PTA (p=0.0316). No significant difference in all-cause mortality was observed.
Boston Scientific Corporation (NYSE: BSX) will host a conference call on October 27, 2021, at 8:00 a.m. EDT to discuss its financial results for the third quarter ending September 30, 2021. The call will feature Mike Mahoney, CEO, and Dan Brennan, CFO, providing insights into the company's performance. A news release with the financial results will precede the call. Interested parties can access the live webcast and replay via investors.bostonscientific.com.
Boston Scientific (NYSE: BSX) announced an agreement to acquire Devoro Medical, developer of the WOLF Thrombectomy® Platform, for approximately $269 million and up to $67 million upon achieving certain milestones. This acquisition aims to enhance Boston Scientific's thrombectomy capabilities, complementing existing products like the EkoSonic™ Endovascular System. The deal is projected to be slightly dilutive to earnings in 2021 but is expected to have a neutral impact on adjusted EPS in 2022. The transaction is anticipated to close in Q4 2021.
Boston Scientific announced positive results from the EPOCH clinical trial for TheraSphere Y-90 Glass Microspheres in treating metastatic colorectal cancer (mCRC) of the liver. The trial met both primary endpoints of progression-free survival (PFS) and hepatic progression-free survival (hPFS). With 428 patients involved, the trial showed that TheraSphere treatment significantly improved PFS and hPFS compared to standard chemotherapy alone. This data will support future FDA submissions, potentially providing broader access to this therapy for mCRC patients.
Boston Scientific Corporation (BSX) will hold a hybrid investor meeting on September 22, 2021, from 8:30 a.m. to 12:30 p.m. EDT, to discuss its financial goals and growth strategies. The meeting will feature business unit overviews, updates on product pipelines, and highlights from key segments including Cardiovascular, MedSurg, and Rhythm and Neuro. Interested parties can register for the live event in Boston or join via webcast. A replay will be available for one year post-event.
Boston Scientific announced the completion of its acquisition of Lumenis Ltd.'s global surgical business for $1.07 billion, which is expected to generate approximately $200 million in revenue for 2021. This acquisition allows Boston Scientific to integrate Lumenis's advanced laser technology into its urology and otolaryngology offerings, enhancing its growth prospects in Europe and Asia. The deal is projected to be slightly dilutive in 2021, with earnings expected to become accretive in 2022 and beyond as synergies are realized and integration progresses.
Boston Scientific Corporation (NYSE: BSX) received FDA 510(k) clearance for its EXALT Model B Single-Use Bronchoscope, intended for bedside procedures in ICU and OR settings. The bronchoscope enhances suction performance and imaging quality, available in three sizes. With over 1.2 million annual procedures using bronchoscopes in the U.S., the single-use design mitigates infection risks associated with reusable devices. Limited market release is expected soon following the completion of CE marking in May 2021.
Boston Scientific has launched the HI-PEITHO clinical trial, investigating the efficacy of the EkoSonic Endovascular System combined with anticoagulation for treating acute, intermediate-high-risk pulmonary embolism (PE). The trial, enrolling up to 544 patients across 65 sites in the U.S. and Europe, aims to compare outcomes against anticoagulation alone. Nearly one million patients are impacted by PE annually in the U.S. and Europe, emphasizing the trial's significance. The study follows patients for a year to assess adverse events and improve clinical guidelines for PE treatment.